Advertisement

Related Videos

Opening Session Panel Discussion

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Opportunities to Optimize Cancer Policies Panel Discussion

Advertisement

Advertisement




Sep
17
Today In Oncology
What Constitutes Clinical Expertise in an AI-Enabled Era
American Cancer Society Urges Men to Understand Their Risk for Prostate Cancer
Two Phase III Trials Explore B7-H3–Directed ADCs in Relapsed SCLC
ADC/Immunotherapy Combination Shows Activity in Treatment-Resistant Nasopharyngeal Carcinoma
Long-Term Benefit Seen With Adjuvant Osimertinib in EGFR-Mutated NSCLC
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo